ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of...
SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The world’s first COVID-19 vaccine to offer immunity against all variants is...
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear –...
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran...
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company...
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company...
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation...
Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the...
Dorval, Quebec--(Newsfile Corp. - June 28, 2022) - West Island Brands Inc. (CSE: WIB) (FSE: 39N0) (OTC Pink: WIBFF) ("West...
● Red Light Holland launches: 'Red Light. Set. Go!' program to work with exceptional local Oregonians from diverse backgrounds who...
- Ohio State Wexner Medical Center and Siemens Healthineers have committed to a new strategic relationship to bring the most...
National Campaign to Feature Eye-Catching Experience in Four Major Metropolitan Cities Beginning June 27 KALAMAZOO, Mich.--(BUSINESS WIRE)--#rebuildinglivestogether--Stryker (NYSE:SYK), one of...
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date,...
PARIS, FRANCE / ACCESSWIRE / June 28, 2022 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-clinical stage...
VANCOUVER, BC / ACCESSWIRE / June 27, 2022 / Verisante Technology Inc. (NEX:VER.H) (the "Company") announces that further to the...